The movement of the stock over the past few years can mainly be attributed to the influence of Dr. Frost. Surely the company has made strategic investments and acquired several companies, but it is important to note that many of those investments may take years to yield tangible returns. The revenue growth has been excellent, but the losses have continued over the years. In any case, the momentum has only increased recently. The volumes over the last two days has been extremely high with nearly 29 million shares being traded. Interestingly, there were around 35 million shares short on September 30. The price on September 30 was below $9, and the stock has traveled quite a distance since then. Based on this, many are attributing the recent rise to a short squeeze. The trigger was the announcement of investment in Zebra Biologics, but the fundamental impact of that may take years to come. The undisclosed investment is relatively speculative as Zebra is into development of next generation antibodies. Dr. Frost has continued to purchase small quantities of the stock consistently, and that could be the real reason for the recent bout of optimism. Frost now controls a total of 152.3 million shares of OPKO Health out of the outstanding 403.6 million shares (37.7%). If he gets aggressive, the large stake makes a strong sentimental and technical impact on the buying pressure. His investments in Biozone Pharmaceuticals (BZNE), which owns the high potential drug delivery technology QuSomes, has also done well. The agreement between OPKO and Biozone, had also made news. The acquisition of PROLOR Biotech, and many others over the last couple of years has helped the stock post remarkable gains. So the stock is trading on future promise, and valuations are not being considered. Still, there is room for more upside as long as Frost is bullish.
